Key Points
- CEO Michael Thomas Henderson sold 40,000 shares on Dec. 4 at an average price of $75.01 for $3,000,400, and combined with a Nov. 13 sale of 20,000 shares the two transactions total about $4.26 million.
- Following the Dec. 4 sale he still owns 1,232,987 shares (worth roughly $92.5 million), so the trades represent partial monetization rather than an exit.
- APGE is trading near its 52-week high (opened $76.75 vs. $77.09 high), has a $5.24 billion market cap, and carries an average analyst rating of "Moderate Buy" with an average price target of $98.38.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 10,900 shares of the business's stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $75.00, for a total value of $817,500.00. Following the completion of the sale, the insider owned 271,108 shares of the company's stock, valued at approximately $20,333,100. This represents a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Carl Dambkowski also recently made the following trade(s):
- On Wednesday, November 5th, Carl Dambkowski sold 10,785 shares of Apogee Therapeutics stock. The stock was sold at an average price of $55.07, for a total transaction of $593,929.95.
- On Wednesday, October 1st, Carl Dambkowski sold 5,110 shares of Apogee Therapeutics stock. The shares were sold at an average price of $39.80, for a total transaction of $203,378.00.
Apogee Therapeutics Price Performance
APGE stock opened at $76.75 on Friday. The company has a market cap of $5.24 billion, a price-to-earnings ratio of -17.52 and a beta of 1.41. The company has a fifty day moving average price of $57.59 and a 200 day moving average price of $45.43. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $77.09.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.11) EPS for the quarter, beating analysts' consensus estimates of ($1.14) by $0.03. As a group, analysts anticipate that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.
Analysts Set New Price Targets
Several brokerages recently issued reports on APGE. Weiss Ratings restated a "sell (d-)" rating on shares of Apogee Therapeutics in a research report on Wednesday, October 8th. Mizuho started coverage on Apogee Therapeutics in a research note on Tuesday, October 21st. They issued an "outperform" rating and a $105.00 target price on the stock. BTIG Research reissued a "buy" rating and issued a $115.00 target price on shares of Apogee Therapeutics in a report on Thursday, October 9th. Wall Street Zen downgraded Apogee Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Finally, Wedbush reiterated an "outperform" rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $98.38.
Read Our Latest Stock Report on APGE
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC lifted its holdings in Apogee Therapeutics by 99.2% in the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company's stock valued at $33,000 after acquiring an additional 383 shares during the period. ANTIPODES PARTNERS Ltd grew its stake in shares of Apogee Therapeutics by 41.2% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company's stock worth $33,000 after purchasing an additional 246 shares during the period. Brooklyn Investment Group purchased a new position in shares of Apogee Therapeutics in the 1st quarter valued at about $42,000. AlphaQuest LLC acquired a new stake in shares of Apogee Therapeutics in the first quarter valued at about $43,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Apogee Therapeutics by 18.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company's stock valued at $77,000 after purchasing an additional 272 shares during the period. Institutional investors and hedge funds own 79.04% of the company's stock.
Apogee Therapeutics Company Profile
(
Get Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
